Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff
Final Annual Results Before Transfer Of Pegfilgrastim Franchise
As Coherus prepares to exit the biosimilars space altogether with the divestment of its Udenyca pegfilgrastim franchise, the firm has set out its annual results for 2024 as well as “organizational streamlining” plans.
